Clinical Trials

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

BreastGastrointestinalHead & Neck

Breast Neoplasms

NCT07158164 2025-11-13

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Phase 4 Recruiting

100 enrolled

Breast Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms

NCT00872625 2025-09-30

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

26 enrolled

Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT00798070 2024-12-18

PANTHER

2,017 enrolled

Breast Neoplasms, Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT02897700 2024-04-17

COC-IDCB

Phase 1 Recruiting

300 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT00036868 2024-03-08

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

90 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT00525759 2023-11-24

ANZAC

40 enrolled

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

1,099 enrolled

Breast Neoplasms

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

1,060 enrolled 20 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

1,925 enrolled 19 charts

Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

1,289 enrolled

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

150 enrolled

Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

2,722 enrolled 14 charts

Breast Neoplasms

NCT01966471 2022-06-14

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

1,846 enrolled 19 charts

Breast Neoplasms

NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Phase 2 Suspended

170 enrolled

Breast Neoplasms

NCT02400567 2022-03-15

NeoPAL

125 enrolled

Neoadjuvant Operable Breast Cancer

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT02132949 2021-09-17

BERENICE

401 enrolled 24 charts

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

429 enrolled

Breast Neoplasms

NCT00014222 2020-10-05

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

2,104 enrolled 11 charts

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

3,509 enrolled

Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00003086 2020-07-14

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1/2 Terminated

12 enrolled

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT00510367 2020-07-10

Primary Breast Cancer Occurring Concomitant With Pregnancy

61 enrolled

Breast Neoplasms

NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

BreastGastrointestinalThoracic

236 enrolled 21 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04031703 2020-04-24

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

647 enrolled

Breast Neoplasms

NCT00002542 2020-04-01

Tamoxifen in Treating Women With High-Risk Breast Cancer

672 enrolled

Breast Neoplasms

NCT02124148 2020-04-01

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

167 enrolled

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT01855828 2020-03-31

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

50 enrolled 13 charts

Her2-Positive Breast Cancer

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Phase 3 Unknown

290 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

2,079 enrolled

Primary Breast Cancer

NCT00820547 2019-10-22

Beverly1

100 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT02115204 2019-10-03

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

2,011 enrolled